A5088200905- Pharmaceutical studies and practices
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Statistical Methods in Clinical Trials
- Pharmaceutical Practices and Patient Outcomes
- Prostate Cancer Treatment and Research
- Medication Adherence and Compliance
- Cancer therapeutics and mechanisms
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Computational Drug Discovery Methods
- Monoclonal and Polyclonal Antibodies Research
- Drug Transport and Resistance Mechanisms
- Pharmacogenetics and Drug Metabolism
- Prostate Cancer Diagnosis and Treatment
- Pediatric Pain Management Techniques
- Ovarian cancer diagnosis and treatment
- Mathematical Biology Tumor Growth
- Prenatal Screening and Diagnostics
- Colorectal Cancer Treatments and Studies
- Ectopic Pregnancy Diagnosis and Management
- Gestational Trophoblastic Disease Studies
- Adolescent and Pediatric Healthcare
- Health Systems, Economic Evaluations, Quality of Life
- Lung Cancer Research Studies
Calvagone (France)
2018-2021
Université Claude Bernard Lyon 1
2011-2020
Hospices Civils de Lyon
2011-2019
Servier (France)
2018-2019
Institut des Hautes Études Scientifiques
2018-2019
Centre de Biophysique Moléculaire
2018-2019
Hôpital de la Croix-Rousse
2018-2019
Centre National de la Recherche Scientifique
2014-2017
Laboratoire de Biométrie et Biologie Evolutive
2014-2017
Hôpital Lyon Sud
2015-2017
Abstract Background In spite of increasing efforts to enhance patient safety, medication errors in hospitalised patients are still relatively common, but with potentially severe consequences. This study aimed assess antineoplastic both affected and intercepted cases terms frequency, severity for patients, costs. Methods A 1-year prospective was conducted order identify the that occurred during chemotherapy treatment cancer at a French university hospital. The potential consequences were...
Human P-glycoprotein (P-gp) controls drugs bioavailability by pumping structurally unrelated out of cells. The X-ray structure the mouse P-gp ortholog has been solved, with two SSS enantiomers or one RRR enantiomer selenohexapeptide inhibitor QZ59, found within putative drug-binding pocket (Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL et al. (2009). Science 323, 1718-1722). This offered first opportunity to localize well-known H and R...
To assess the suitability and potential cost savings, from both hospital community perspective, of prescribed oral liquid medicine substitution with acceptable solid forms for children over 2 years.Oral medicines dispensed a paediatric (UK) in 1 week were assessed by screening existence form alternative evaluating acceptability available form, firstly related to dose secondly size depending on child's age. Costs calculated based providing treatment 28 days or duration short term...
In low-risk gestational trophoblastic neoplasia (GTN) patients, a predictive marker for early identification of methotrexate (MTX) resistance would be useful. We previously demonstrated that kinetic modelling human chorionic gonadotrophin (hCG) measurements could provide such marker. Here we validate this approach in large independent patient cohort. Serum hCG 800 GTN patients treated with MTX were analysed. The cohort was divided into Model and Test data sets. kinetics described from...
For the purpose of developing a longitudinal model to predict hand-and-foot syndrome (HFS) dynamics in patients receiving capecitabine, data from two large phase III studies were used. Of 595 capecitabine arms, 400 randomly selected build model, and other 195 assigned for validation. A score risk HFS was modeled using proportional odds sigmoidal maximum effect driven by accumulation as estimated through kinetic–pharmacodynamic Markov process. The lower calculated creatinine clearance value...
The main objective of the present study was to establish relationships between CA-125 kinetics and tumour size changes during treatment.The data from CALYPSO-randomised phase III trial, comparing two platinum-based regimens in recurrent ovarian cancer (ROC) patients, randomly split into a 'learning set' estimate model parameters 'validation validate performances. A kinetic-pharmacodynamic semi-mechanistic built describe chemotherapy. ability predict response induced by chemotherapy, based on...
Assessment of treatment efficacy in metastatic castration‐resistant prostate cancer (mCRPC) is limited by frequent nonmeasurable bone metastases. The count circulating tumor cells (CTCs) a promising surrogate marker that may replace the widely used prostate‐specific antigen (PSA). purpose this study was to quantify dynamic relationships between longitudinal kinetics these markers during patients with mCRPC. Data from 223 mCRPC treated chemotherapy and/or hormonotherapy were analyzed for up 6...
Numerous oral anticancer chemotherapies are available. Non-adherence or over-adherence to these can lead lowered efficacy and increased risk of adverse events. The objective this study was identify patients' adherence profiles using a qualitative–quantitative method. A capecitabine treatment initiated for 38 patients with advanced breast colorectal cancer. At inclusion, information on beliefs reported questionnaire. Later, Information relation obtained from sub-group during an interview...
The aim of this retrospective cohort study was to investigate the incidence delayed methotrexate elimination in patients treated with high-dose (≥1 g/m2 ) for haematological malignancy and identify impact interacting drugs, especially proton-pump inhibitors (PPIs) ranitidine. All over a 6 year period haematology department Lyon Sud University Hospital (Hospices Civils de Lyon, France) were included. Potential risk factors tested generalized linear model by univariate analysis: patient age,...
Abstract: Trastuzumab is a monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). HER2 amplified or overexpressed in about 15% of breast cancers and associated with aggressive disease. Clinical benefits trastuzumab have been established treatment both early metastatic HER2-positive cancer. Patients cancer to be treated for one year combination sequentially after chemotherapy. This requires that intravenously infused over 30–90 minutes every 3 weeks which...
Abetalipoproteinemia (ABL) and chylomicron retention disease (CMRD) are extremely rare recessive forms of hypobetalipoproteinemia characterized by intestinal lipid malabsorption severe vitamin E deficiency. Vitamin is often supplemented in the form fat-soluble acetate, but fat considerably limits correction In this crossover study, we administered two different E, tocofersolan (a water-soluble derivative RRR-α-tocopherol) α-tocopherol to three patients with ABL four CMRD. The aims study were...
The concentration-effect relationship of rituximab in follicular lymphoma (FL) was previously described using pharmacokinetic-pharmacodynamic (PK-PD) modelling. influence genetic polymorphism FCGR3A on efficacy FL patients included this PK-PD model. Previous studies suggest that increasing the dose and/or number infusions may lead to a better clinical response FL.
Rituximab has dramatically improved the survival of patients with non-Hodgkin's lymphomas (NHL), but dosing regimen currently used should be optimized. However, concentration-effect relationship rituximab never been described by pharmacokinetic-pharmacodynamic (PK-PD) modelling, precluding simulation new regimens. The aim this study was to develop a PK-PD model in relapsed/resistant follicular NHL (FL).A describing between concentrations and progression-free (PFS) developed using data...
Abstract PURPOSES Using population kinetic approach, we modeled PSA decline equations in patients with prostate cancer after radical prostatectomy (RP). We looked for relationships between early decrease profile, characterized by clearance (CL ) or half‐life (HL ), and the 2‐year biochemical relapse free survival (bRFS). PATIENTS AND METHODS performed a retrospective study on 55 treated RP at least 2 measurements post‐operative month. A model was investigated NONMEM®. The prognostic factors...